Who Owns Piramal Critical Care?

Piramal Critical Care operates under Piramal Pharma Limited's sustainability framework, built on four pillars: Business Resilience, Quality and Excellence, Responsible Operations, and Stakeholder Centricity. The company has embedded sustainability into its core business strategy and established over 50 time-bound sustainability targets.

The division maintains manufacturing facilities in the U.S. and India that comply with environmental regulations and sustainability standards. The company focuses on responsible manufacturing practices, waste reduction, and energy efficiency across its production sites. As part of Piramal Pharma's environmental commitments, the division participates in corporate-wide initiatives to minimize environmental impact.

Piramal Critical Care's manufacturing facilities have been inspected by multiple regulatory authorities, including the U.S. FDA, UK MHRA, and other global regulators. The 2025 FDA Form 483 at the Lexington facility resulted in four observations classified as Voluntary Action Indicated, which relates to procedural enhancements rather than critical manufacturing deficiencies. The company prepared detailed responses within regulatory timelines.

The division collaborates with the Piramal Foundation on CSR programs focused on healthcare access, education, and community development. The Piramal Foundation operates initiatives in rural healthcare, education, and women's empowerment across India.

With a workforce of over 400 employees representing 20 nationalities across 16 countries, Piramal Critical Care maintains ethical standards and corporate governance practices. The company's stakeholder-centric approach considers the interests of patients, healthcare providers, employees, communities, and shareholders.

The division's stated purpose is "Saving and improving patients' lives." This purpose guides its sustainability initiatives and patient centricity campaigns, which focus on putting patients at the center of business decisions.

Piramal Critical Care has been recognized for its market leadership in inhalational anesthetics and its commitment to sustainability.

In 2025, Piramal Pharma Limited achieved a notable score increase on the S&P Global Corporate Sustainability Assessment (CSA). This achievement reflects the company's integration of ESG principles into its core business strategy and Piramal Critical Care's contribution to the company's overall sustainability performance.

Piramal Pharma released its fourth annual Sustainability Report in 2025, outlining progress across 28 material topics supported by 50-plus time-bound targets. The report highlighted the company's shift from basic ESG compliance to integrating sustainability into its core business strategy.

The division's manufacturing facilities have successfully cleared inspections by multiple global regulatory authorities, including the U.S. FDA, UK MHRA, and other regulatory bodies. These inspections represent recognition of the division's manufacturing standards and regulatory compliance.

Piramal Critical Care is consistently recognized as one of the leaders in inhaled anesthetics and a global player in hospital generics. This market leadership position is acknowledged in industry reports and analyst coverage.

The division's workforce diversity, with over 400 employees representing 20 nationalities across 16 countries, has been recognized as a strength in global pharmaceutical operations. This diversity contributes to the company's ability to serve healthcare markets globally.

Piramal Critical Care has not experienced any major product recalls as of August 2026. The most significant regulatory issue was a 2025 FDA Form 483 at the Lexington, Kentucky facility.

FDA Form 483 at Lexington Facility (2025): Piramal Pharma's Lexington, Kentucky facility received a U.S. FDA Form 483 following a Good Manufacturing Practices inspection. The inspection resulted in four regulatory observations classified as Voluntary Action Indicated (VAI). The VAI classification indicates that the FDA found objectionable conditions but was not prepared to take or recommend administrative or regulatory action. This classification is less severe than an Official Action Indicated (OAI) status, which would require more immediate corrective measures.

The observations focused on procedural enhancements rather than critical manufacturing deficiencies. The issues were specifically related to procedural improvements rather than problems with product quality or safety. Piramal Pharma confirmed it was preparing a detailed response to address all observations within regulatory timelines.

No Major Product Recalls: Piramal Critical Care has not experienced any major product recalls that would indicate systemic quality issues. The company's focus on inhalational anesthetics and complex hospital generics requires stringent quality control measures, and the division has maintained compliance with these requirements.

Limited Public Controversies: Piramal Critical Care has maintained a low public profile with minimal controversies. The company's business-to-business focus on healthcare providers and hospitals, combined with its emphasis on essential critical care medications, has helped it avoid the types of public scrutiny that affect consumer-facing pharmaceutical companies.

Regulatory Compliance Track Record: Despite the 2025 FDA observation, the division's manufacturing facilities in the U.S. and India have successfully cleared periodic inspections by multiple regulatory authorities, including the U.S. FDA, UK MHRA, and other global regulators. This compliance record reflects the company's investment in quality systems and manufacturing excellence.